Chronic reduction of fasting glycemia with insulin glargine improves first-and second-phase insulin secretion in patients with type 2 diabetes

Diabetes Care

Volumn 34, Issue 9, 2011, Pages 2048-2053

  Pennartz, Christian ^a   Schenker, Nina ^a   Menge, Björn A ^a   Schmidt, Wolfgang E ^a   Nauck, Michael A ^b   Meier, Juris J ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b Bad Lauterberg Diabetes Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; METFORMIN; GLARGINE; LONG ACTING INSULIN;

ADD ON THERAPY; ADULT; ANTIDIABETIC ACTIVITY; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; TREATMENT DURATION; AGED; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SECRETION;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; INSULIN; INSULIN, LONG-ACTING; MALE; MIDDLE AGED;

EID: 82155198455     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0471     Document Type: Article

References (25)

1. Pfeifer MA, Halter JB, Porte D Jr. Insulin secretion in diabetes mellitus. Am J Med 1981;70:579-588 (Pubitemid 11153856)
2. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr. Diminished B cell secretory capacity in patients with noninsulindependent diabetes mellitus. J Clin Invest 1984;74:1318-1328 (Pubitemid 15206828)
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-110 (Pubitemid 36042113)
4. Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004;89:3629-3643 (Pubitemid 39071447)
5. Godsland IF, Jeffs JA, Johnston DG. Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 2004;47:1157-1166 (Pubitemid 39093312)
6. Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976;42:222-229
7. Boden G, Ruiz J, Kim CJ, Chen X. Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects. Am J Physiol 1996;270:E251-E258
8. Ritzel RA, Hansen JB, Veldhuis JD, Butler PC. Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose. J Clin Endocrinol Metab 2004;89:795-805 (Pubitemid 38269895)
9. Brown RJ, Rother KI. Effects of betacell rest on beta-cell function: a review of clinical and preclinical data. Pediatr Diabetes 2008;9:14-22 (Pubitemid 351784991)
10. Carr RD, Brand CL, Bodvarsdottir TB, Hansen JB, Sturis J.NN414, a SUR1/Kir6.2-selective potassium channel opener, reduces blood glucose and improves glucose tolerance in the VDF Zucker rat. Diabetes 2003;52:2513-2518 (Pubitemid 37210539)
11. Cusi K, Cunningham GR, Comstock JP. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care 1995;18:843-851
12. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985;34:222-234 (Pubitemid 15134779)
13. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-1760 (Pubitemid 351697950)
14. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086 (Pubitemid 37339502)
15. Hovorka R, Soons PA, Young MA. ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 1996;50:253-264 (Pubitemid 26308809)
16. Turner RC, McCarthy ST, Holman RR, Harris E. Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. BMJ 1976;1:1252-1254
17. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first- and secondphase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005;90:5991-5997 (Pubitemid 41606516)
18. Laedtke T, Kjems L, Pørksen N, et al. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am J Physiol Endocrinol Metab 2000;279:E520-E528
19. Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004;53(Suppl. 1):S119-S124 (Pubitemid 38168703)
20. Ho E, Chen G, Bray TM. Supplementation of N-acetylcysteine inhibits NFkappaB activation and protects against alloxaninduced diabetes in CD-1 mice. FASEB J 1999;13:1845-1854 (Pubitemid 29473348)
21. Kubisch HM,Wang J, Bray TM, Phillips JP. Targeted overexpression of Cu/Zn superoxide dismutase protects pancreatic betacells against oxidative stress.Diabetes 1997;46:1563-1566 (Pubitemid 27411230)
22. Meier JJ, Kjems LL, Veldhuis JD, Lefèbvre P, Butler PC. Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis.Diabetes 2006;55:1051-1056 (Pubitemid 44100181)
23. Linn T, Fischer B, Soydan N, Eckhard M, Ehl J, Kunz C, Bretzel RG. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:3839-3846
24. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA; Orals Plus Apidra and LANTUS (OPAL) study group. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008;10:1178-1185
25. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine andmetformin: a proof-of-concept study. Diabetes Care 2010;33:1509-1515